GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
01 févr. 2024 16h30 HE
|
GeneDx Holdings Corp.
GeneDx management will host a conference call at 4:30 p.m. Eastern Time on February 20, 2024 to discuss 2023 results and share full year 2024 guidance.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 janv. 2024 16h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23,...
GeneDx Announces Preliminary 2023 Financial Results
08 janv. 2024 08h55 HE
|
GeneDx Holdings Corp.
Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations of more than $57M.
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
01 déc. 2023 08h30 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Dec. 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced new data to be...
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
28 nov. 2023 16h05 HE
|
GeneDx Holdings Corp.
GeneDx company management will participate in the 6th Annual Evercore ISI HealthCONx Conference.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20 nov. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Nov. 20, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of November 17,...
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
30 oct. 2023 16h05 HE
|
GeneDx Holdings Corp.
Reported total revenue of $53M with more than 40% year-over-year growth of exome and genome test revenue Expanded gross margins to 48% in continuing operations and delivered 52% year-over-year...
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
09 oct. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Oct. 09, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
22 sept. 2023 16h05 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 22, 2023 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of October 1,...
GeneDx Announces Evolution of Executive Leadership Team
11 sept. 2023 08h00 HE
|
GeneDx Holdings Corp.
STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and...